ArticleNews reportPHN-06142026-11-02 06:27 CT

What new weight-loss drugs are coming?

Source · AOL.com

TLDR

AOL's article surveys experimental weight-loss drugs from several companies, including Eli Lilly, Novo Nordisk, Amgen and Roche. It reports 20% body-weight loss in a yearlong MariTide trial and average weight loss of 15.5% in an enicepatide trial involving participants with Type 2 diabetes.

01—Key points

01The article lists retatrutide and Cagrisema among weight-loss drugs in development, but provides no trial results for either.
02Amgen's MariTide is reportedly undergoing six late-stage trials covering obesity and related conditions.
03The article reports that Roche's enicepatide lowered blood sugar, with two late-stage studies pending in early 2027.

Why it matters Editorial

The report highlights ongoing development of peptide-related weight-loss treatments, while providing limited safety and approval information.

Read the original at AOL.com↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.